Louis G Lange - Net Worth and Insider Trading
Louis G Lange Net Worth
The estimated net worth of Louis G Lange is at least $20 Million dollars as of 2024-05-17. Louis G Lange is the Director of Audentes Therapeutics Inc and owns about 315,375 shares of Audentes Therapeutics Inc (BOLD) stock worth over $19 Million. Louis G Lange is the Director of Esperion Therapeutics Inc and owns about 215,517 shares of Esperion Therapeutics Inc (ESPR) stock worth over $558,189. Louis G Lange is also the Director of NewAmsterdam Pharma Co NV and owns about 24,878 shares of NewAmsterdam Pharma Co NV (NAMS) stock worth over $498,804. Details can be seen in Louis G Lange's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Louis G Lange has not made any transactions after 2024-02-13 and currently still holds the listed stock(s).
Transaction Summary of Louis G Lange
Louis G Lange Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Louis G Lange owns 7 companies in total, including Audentes Therapeutics Inc (BOLD) , CymaBay Therapeutics Inc (CBAY) , and Esperion Therapeutics Inc (ESPR) among others .
Click here to see the complete history of Louis G Lange’s form 4 insider trades.
Insider Ownership Summary of Louis G Lange
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| BOLD | Audentes Therapeutics Inc | 2020-01-15 | director |
| CBAY | CymaBay Therapeutics Inc | 2013-10-11 | director |
| ESPR | Esperion Therapeutics Inc | 2013-07-01 | director |
 | | 2009-04-17 | EVP Cardiovascular Therapeutic |
| | 2021-12-02 | director |
| | 2022-09-16 | director |
| | 2022-09-16 | director |
Louis G Lange Latest Holdings Summary
Louis G Lange currently owns a total of 3 stocks. Among these stocks, Louis G Lange owns 315,375 shares of Audentes Therapeutics Inc (BOLD) as of December 23, 2019, with a value of $19 Million and a weighting of 94.71%. Louis G Lange owns 215,517 shares of Esperion Therapeutics Inc (ESPR) as of July 1, 2013, with a value of $558,189 and a weighting of 2.8%. Louis G Lange also owns 24,878 shares of NewAmsterdam Pharma Co NV (NAMS) as of February 13, 2024, with a value of $498,804 and a weighting of 2.5%.
Latest Holdings of Louis G Lange
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| BOLD | Audentes Therapeutics Inc | 2019-12-23 | 315,375 | 59.97 | 18,913,039 |
| ESPR | Esperion Therapeutics Inc | 2013-07-01 | 215,517 | 2.59 | 558,189 |
| NAMS | NewAmsterdam Pharma Co NV | 2024-02-13 | 24,878 | 20.05 | 498,804 |
Holding Weightings of Louis G Lange
Louis G Lange Form 4 Trading Tracker
According to the SEC Form 4 filings, Louis G Lange has made a total of 3 transactions in Audentes Therapeutics Inc (BOLD) over the past 5 years, including 0 buys and 3 sells. The most-recent trade in Audentes Therapeutics Inc is the sale of 11,000 shares on December 23, 2019, which brought Louis G Lange around $655,600.
According to the SEC Form 4 filings, Louis G Lange has made a total of 0 transactions in Esperion Therapeutics Inc (ESPR) over the past 5 years. The most-recent trade in Esperion Therapeutics Inc is the acquisition of 14,214 shares on July 1, 2013, which cost Louis G Lange around $198,996.
According to the SEC Form 4 filings, Louis G Lange has made a total of 1 transactions in NewAmsterdam Pharma Co NV (NAMS) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in NewAmsterdam Pharma Co NV is the acquisition of 5,000 shares on February 13, 2024, which cost Louis G Lange around $95,000.
Insider Trading History of Louis G Lange
- 1
Louis G Lange Trading Performance
GuruFocus tracks the stock performance after each of Louis G Lange's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Louis G Lange is 17.87%. GuruFocus also compares Louis G Lange's trading performance to market benchmark return within the same time period. The performance of stocks bought by Louis G Lange within 3 months outperforms 1 times out of 2 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Louis G Lange's insider trading performs compared to the benchmark.
Performance of Louis G Lange
Average Return
Outperforming Transactions
| 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
|---|---|---|---|---|---|---|
| Return(%) | 19.24 | | | | | |
| Relative Return to S&P 500(%) | 14.26 | | | | | |
Louis G Lange Ownership Network
Louis G Lange Owned Company Details
What does Audentes Therapeutics Inc do?
Who are the key executives at Audentes Therapeutics Inc?
Louis G Lange is the director of Audentes Therapeutics Inc. Other key executives at Audentes Therapeutics Inc include President and COO Natalie C. Holles , SVP & Chief Medical Officer Edward R. Conner , and Executive Vice President & CFO Thomas P Soloway .
Audentes Therapeutics Inc (BOLD) Insider Trades Summary
In summary, during the past 3 months, insiders sold 0 shares of Audentes Therapeutics Inc (BOLD) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Audentes Therapeutics Inc (BOLD) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.
Audentes Therapeutics Inc (BOLD)'s detailed insider trading history can be found in Insider Trading Tracker table.
Audentes Therapeutics Inc Insider Transactions
Louis G Lange Mailing Address
Above is the net worth, insider trading, and ownership report for Louis G Lange. You might contact Louis G Lange via mailing address: 3172 Porter Drive, Palo Alto Ca 94034.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
